- Home
- ACAD vs MGNI Comparison
ACAD vs MGNI Comparison
Compare ACAD & MGNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- MGNI
- Stock Information
- Founded
- ACAD 1993
- MGNI 2007
- Country
- ACAD United States
- MGNI United States
- Employees
- ACAD N/A
- MGNI N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- MGNI Computer Software: Programming Data Processing
- Sector
- ACAD Health Care
- MGNI Technology
- Exchange
- ACAD Nasdaq
- MGNI Nasdaq
- Market Cap
- ACAD 2.5B
- MGNI 2.4B
- IPO Year
- ACAD 2004
- MGNI N/A
- Fundamental
- Price
- ACAD $22.71
- MGNI $18.72
- Analyst Decision
- ACAD Buy
- MGNI Strong Buy
- Analyst Count
- ACAD 16
- MGNI 13
- Target Price
- ACAD $27.00
- MGNI $19.23
- AVG Volume (30 Days)
- ACAD 1.6M
- MGNI 1.9M
- Earning Date
- ACAD 08-05-2025
- MGNI 08-06-2025
- Dividend Yield
- ACAD N/A
- MGNI N/A
- EPS Growth
- ACAD N/A
- MGNI N/A
- EPS
- ACAD 1.37
- MGNI 0.21
- Revenue
- ACAD $996,283,000.00
- MGNI $674,622,000.00
- Revenue This Year
- ACAD $13.39
- MGNI $0.32
- Revenue Next Year
- ACAD $10.59
- MGNI $11.02
- P/E Ratio
- ACAD $16.65
- MGNI $87.36
- Revenue Growth
- ACAD 22.42
- MGNI 5.59
- 52 Week Low
- ACAD $13.40
- MGNI $8.22
- 52 Week High
- ACAD $25.23
- MGNI $21.29
- Technical
- Relative Strength Index (RSI)
- ACAD 66.04
- MGNI 69.84
- Support Level
- ACAD $21.35
- MGNI $16.99
- Resistance Level
- ACAD $22.69
- MGNI $18.63
- Average True Range (ATR)
- ACAD 0.76
- MGNI 0.62
- MACD
- ACAD -0.13
- MGNI 0.03
- Stochastic Oscillator
- ACAD 70.76
- MGNI 80.91
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About MGNI Magnite Inc.
Magnite Inc is one of the supply-side platform providers, or SSP, in online advertising. The firm generate its revenue from the programmatic sale of CTV ad inventory, from mobile online sites and apps, and the remaining from websites accessed via computer.